Steven Plachtyna
Vice President @ Ally Bridge Group
New York, United States
Steven Plachtyna is a Series B investor at Ally Bridge Group in New York focused on Health Care and Biotechnology. Steven Plachtyna is based out of New York, New York, and is the VP of Ally Bridge Group and also Board of Directors of Biobeat. Steven Plachtyna attended the Cornell University.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Steven Plachtyna invests in
Stages Steven Plachtyna invests in
Countries Steven Plachtyna invests in
Investment Focus
Industry
- Health Care 2 (67%)
- Biotechnology 2 (67%)
- Medical Device 2 (67%)
- Analytics 1 (33%)
- Wearables 1 (33%)
Stage
- Series B 1 (33%)
- Series E 1 (33%)
- Funding Round 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Biobeat
|
Biobeat develops a wearable device for continuous, noninvasive, accurate, medical-grade monitoring of vital signs that include blood pressure, oxygen saturation, respiratory rate, heart rate, consciousness, cardiac output, stroke volume, body temperature, steps, and sweat. Its wearable device automatically uploads the recorded data to asmartphone-based application and to the cloud, where the application can monitor it remotely. Caretakers can intervene if needed, and users can receive alerts directly from the app. This provides caretakers with an important tool to assist in disease management and optimize clinical outcomes. The Biobeat system also facilitates remote monitoring of patients with a variety of medical issues. Ultimately, this solution allows patients to be treated in their homes. It can monitor stationary patients as well as those who perform outdoor activities. In 2018, Biobeat received FDA 510K clearance (K181006) for its monitoring system and partnered with DRIVe, a division of the Biomedical Advanced Research and Development Authority, to develop a wearable monitoring device that diagnoses the flu and infections before any symptoms appear. In August 2019, Biobeat received 510K FDA clearance for its patch and watch. | $50M / Series B / Dec 30, 2025 | |
Cardiac Dimensions
|
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $53M / Series E / Mar 20, 2025 | |
VitalConnect
|
VitalConnect develops wearable biosensor technology designed for wireless patient monitoring. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms. The company's products are designed for inpatient and outpatientsettings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. | $100M |
Co-Investors
Revelation Partners
2 deals together
Elevage Medical Technologies
1 deal together
Essex Woodlands Healthcare Partners
1 deal together
Claret Capital Partners
1 deal together
Horizon 3
1 deal together
Horizon 3 Healthcare
1 deal together
About Ally Bridge Group
Ally Bridge Group is a healthcare-focused investment group committed to venture and growth capital, buyout, and hedge fund investing. Ally Bridge Group focuses on both private and public equity investments, with a particular emphasis on pioneering life sciences companies and technologies. The firm is dedicated to bridging the gap betweengroundbreaking healthcare innovations and global markets. By leveraging its expertise and extensive network, Ally Bridge Group supports the growth and development of its portfolio companies. Its investment strategy is centered on transformative technologies and solutions that address major unmet medical needs.
Ally Bridge Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Steven Plachtyna
Vice President
|
|||
|
Arthur Kuan
Founding Member
|
|||
|
David Nikodem
Managing Director
|
|||
|
Dayu Teng
Venture Partner
|
|||
|
Frank Yu
Founder and CEO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Steven Plachtyna invest in?
Steven Plachtyna invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series E stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Steven Plachtyna last invest?
The most recent investment recorded for Steven Plachtyna closed in Dec 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
